Physician profile
Raymond Oconnell Schultz
NPI 1124014824
$8,870.55
in general payments reported to CMS, 2019-2025
27 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 82% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,639 · 2020: $261 · 2021: $404 · 2022: $995 · 2023: $861 · 2024: $1,899 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Education: $38.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Education | $38.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,208.00 | 2019-2022 | |
| Innovation Technologies INC | $2,153.81 | 2022-2025 | Irrisept |
| Polynovo North America LLC | $598.68 | 2023-2025 | Novosorb Btm |
| W. L. Gore & Associates, INC. | $500.00 | 2024 | Product In Development |
| Tela Bio, INC. | $499.13 | 2019-2024 | Ovitex 2s |
| Abbvie INC. | $455.69 | 2023-2025 | Alloderm, Natrelle Saline-Filled Breast Implants |
| Integra Lifesciences Corporation | $392.03 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Endo Pharmaceuticals INC. | $389.50 | 2019-2023 | Xiaflex |
| Smith+Nephew, INC. | $314.81 | 2019-2023 | Grafix Pl, Oasis, Renasys Touch |
| Musculoskeletal Transplant Foundation INC. | $248.05 | 2019-2025 | |
| Kci USA, INC. | $185.60 | 2019-2022 | |
| Galderma Laboratories, L.P. | $125.62 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $117.35 | 2022-2023 | Seglentis |
| Organogenesis INC. | $116.93 | 2020-2025 | Simplimax |
| Medela LLC | $81.71 | 2019-2024 | Invia Motion Endure |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $80.48 | 2019-2023 | Bridion |
| Heron Therapeutics, INC. | $70.33 | 2021-2022 | |
| Polymedics Innovations INC. | $58.01 | 2024-2025 | |
| Endo USA, INC. | $53.27 | 2024-2025 | Xiaflex |
| Solventum Corporation | $51.07 | 2024-2025 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Sanara Medtech INC. | $40.39 | 2024 | Celleraterx |
| Convatec INC. | $32.03 | 2023 | |
| Kerecis Limited | $25.10 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Medtronic, INC. | $23.93 | 2025 | Transorb |
| Acera Surgical, INC. | $20.35 | 2025 | Restrata Wound Matrix |
| Acelrx Pharmaceuticals, INC. | $16.95 | 2021 | |
| Davol INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.